Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis

Objectives: To establish whether magnetisation transfer ratio (MTR) histograms are sensitive to change in normal appearing grey matter (NAGM) in early relapsing-remitting multiple sclerosis (RRMS) in the absence of significant disability; and to assess whether grey or white matter MTR measures are associated with clinical measures of impairment in early RRMS Methods: 38 patients were studied (mean disease duration 1.9 years (range 0.5 to 3.7); median expanded disability status scale (EDSS) 1.5 (0 to 3)), along with 35 healthy controls. MTR was determined from proton density weighted images with and without MT presaturation. SPM99 was used to generate normal appearing white matter (NAWM) and NAGM segments of the MTR map, and partial voxels were minimised with a 10 pu threshold and voxel erosions. Mean MTR was calculated from the tissue segments. Atrophy measures were determined using a 3D fast spoiled gradient recall sequence from 37 patients and 17 controls. Results: Mean NAGM and NAWM MTR were both reduced in early RRMS (NAGM MTR: 31.9 pu in patients v 32.2 pu in controls; p<0.001; NAWM MTR: 37.9 v 38.3 pu, p = 0.001). Brain parenchymal fraction (BPF) correlated with NAGM MTR, but when BPF was included as a covariate NAGM MTR was still lower in the patients (p = 0.009). EDSS correlated with NAGM MTR (r = 0.446 p = 0.005). Conclusions: In early RRMS, grey matter MTR abnormality is apparent. The correlation with mild clinical impairment (in this essentially non-disabled cohort) suggests that NAGM MTR could be a clinically relevant surrogate marker in therapeutic trials.

[1]  P. M. Matthews,et al.  Evidence of early cortical atrophy in MS , 2003, Neurology.

[2]  M. Horsfield,et al.  A 6‐year clinical and MRI follow‐up study of patients with relapsing–remitting multiple sclerosis treated with Interferon‐beta , 2002, European journal of neurology.

[3]  Wolfgang Brück,et al.  Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. , 2002, Brain : a journal of neurology.

[4]  P Kapeller,et al.  Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.

[5]  G. Barker,et al.  Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS , 2002, Neurology.

[6]  F Barkhof,et al.  The role of MRI as a surrogate outcome measure in multiple sclerosis , 2002, Multiple sclerosis.

[7]  A J Thompson,et al.  Brain atrophy in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.

[8]  David H. Miller,et al.  The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis , 2002, Journal of Neurology.

[9]  Jayaram K. Udupa,et al.  Magnetization Transfer Ratio Histogram Analysis of Normal-Appearing Gray Matter and Normal-Appearing White Matter in Multiple Sclerosis , 2002, Journal of computer assisted tomography.

[10]  L. Kappos,et al.  Clinical–MRI correlations in a European trial of interferon beta-1b in secondary progressive MS , 2001, Neurology.

[11]  B. Trapp,et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.

[12]  B K Rutt,et al.  Magnetization transfer and multicomponent T2 relaxation measurements with histopathologic correlation in an experimental model of MS , 2000, Journal of magnetic resonance imaging : JMRI.

[13]  Nikos Evangelou,et al.  Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis , 2000, Annals of neurology.

[14]  F. Barkhof,et al.  Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.

[15]  S. Reingold,et al.  The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment , 1999, Multiple sclerosis.

[16]  A J Thompson,et al.  Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. , 1999, Neurology.

[17]  F. Barkhof,et al.  Cortical lesions in multiple sclerosis. , 1999, Brain : a journal of neurology.

[18]  ichard,et al.  AXONAL TRANSECTION IN THE LESIONS OF MULTIPLE SCLEROSIS , 1998 .

[19]  F. Lublin,et al.  Management of patients receiving interferon beta-1b for multiple sclerosis , 1996, Neurology.

[20]  G. Barker,et al.  An interleaved sequence for accurate and reproducible clinical measurement of magnetization transfer ratio. , 1996, Magnetic resonance imaging.

[21]  M Filippi,et al.  A Magnetization Transfer Imaging Study of Normal-Appearing White Matter in Multiple Sclerosis , 1995, Neurology.

[22]  R I Grossman,et al.  Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. , 1992, Radiology.

[23]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[24]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[25]  I. Allen,et al.  A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis , 1979, Journal of the Neurological Sciences.